Clinical trial
Use of Omalizumab Will Increase the Pregnancy Rate, Proof of Concept Study, Where Women With Asthma and Infertility Will be Treated Three Times With Weight and IgE Balanced Dosis at the First Day of Their Period Bleeding
NCT03727971 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Omalizumab Will Increase the Pregnancy Rate, Proof of Concept Study, Where Women With Asthma and Infertility Will be Treated Three Times With Weight and IgE Balanced Dosis at the First Day of Their Period Bleeding
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 1, 2019
- Completion date
- December 31, 2024
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.